Bactiguard wins another tender in Sweden
Bactiguard has won a tender for urinary catheters for the southern region (Region Skåne) in Sweden, which enables healthcare providers in both primary and secondary care to purchase Bactiguards’ anti-infective urinary catheters from 1 August 2017. The contract initially runs until 30 April 2018 and can be extended on an annual basis until 30 April 2020.
"We have really had a successful start this year with respect to tenders in Sweden. Our infection prevention technology is gaining broader and broader acceptance and Region Skåne now follows the Stockholm County Council's example in procuring our urinary catheters.The Western region in Sweden (Västra Götalandsregionen) has also introduced an infection prevention category in their ongoing tender. The increased focus on antibiotic resistance is very timely for us, "said Nina Nilsson, SVP Sales and Marketing.
"Just like in Stockholm, the contract for Region Skåne covers both primary and secondary care, which makes it easier for patients who are normally treated by primary care providers, but sometimes need to seek emergency care for example in case of an urinary tract infection," Nina Nilsson continues.
The contract runs from August this year to April 2018, with the option to extend it on an annual basis. It is a supplement to the current contract for urology products and covers the Bactiguard BIP Foley Catheter Silicone, a product that has been evaluated by the region for some time already.
For further information, please contact:
Nina Nilsson, SVP Sales and Marketing, mobile: +46 70 214 87 49
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection protection solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner CR Bard, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 60 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives on www.bactiguard.com